top of page
123yannxiw

5meo Mipt: The psychedelic AI found



A psychedelic drug selected by artificial intelligence for its promise to precisely target mental illness faces a critical test at the Food and Drug Administration.

The FDA is expected to decide in the next few weeks whether to approve an application by San Francisco-based Mindstate Design Labs for a clinical trial of the psychedelic drug 5-MeO-MiPT.


Why it matters: Approval would mark a win for two hot areas in drug development: psychedelics thought to have promise in treating conditions like depression and post-traumatic stress disorder, and AI, which drugmakers hope will speed products to market.

Mindstate Design Labs picked the drug, also known as moxy, using an AI model it built and trained on more than 70,000 “trip reports” of people using psychedelics pulled from drug forums, books, clinical trials, Reddit and the dark web, Mindstate CEO Dillan DiNardo told Erin.


Should the FDA sign off, the plan is to conduct a 50-participant Phase I trial at the Centre for Human Drug Research in the Netherlands. Participants will receive moxy and undergo brain imaging to help the researchers better understand how the drug affects brain activity.

Future trials would explore combining 5-MeO-MiPT with other drugs that affect brain function.


The goal is to create treatments for mental health conditions such as depression, anxiety or PTSD. If it works, the technology could allow Mindstate to pursue more targeted conditions like stuttering.

About 1  in 5 adults in the U.S. experience some form of mental illness, according to the National Institute of Mental Health.


What’s next? If the Mindstate team can show their machine-learning model works to predict the effects of moxy in combination with other drugs, it will open new treatment possibilities.

“For the first time then, we have this proven ability to intentionally design states of consciousness,” DiNardo said. “From there, many opportunities open up, in different therapeutic areas, commercial areas, maybe even eventually turning around and using that computational architecture to develop better AI systems.”


Alexander “Sasha” Shulgin, the renowned chemist and psychopharmacologist, is truly a pioneer in the world of psychedelics. Over the course of his remarkable career, he synthesized and explored an astonishing number of novel psychoactive compounds. By his own accounts, he created nearly 250 distinct psychedelic drugs including the 5meo Mipt. His groundbreaking work has left an indelible mark on the field, earning him the well-deserved title of the "godfather of psychedelics"



1 view0 comments

Comments


bottom of page